Blood Transfusion Diagnostics Market Size to Hit USD 8.67 Billion by 2035 as Automated Testing and AI-Driven Blood Safety Solutions Accelerate Growth | SNS Insider

The global blood transfusion diagnostics market is projected to grow from USD 4.88 billion in 2025 to USD 8.67 billion by 2035, with a CAGR of 5.91%. Growth is driven by increasing demand for automated testing, AI-driven blood safety solutions, molecular diagnostics, and rising prevalence of blood-related disorders. North America leads the market with 40.46% share, while Asia Pacific shows the fastest growth at 8.62% CAGR.

07/24/2026, 9:30 AM • GlobeNewswire

Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035

The global cancer biomarkers market is projected to grow from $25.9 billion in 2026 to $37.8 billion by 2035, with a CAGR of 4.3%. Growth is driven by rising cancer incidence, personalized medicine adoption, advances in NGS and liquid biopsy technologies, and increased biomarker-driven diagnostics. HER2 testing leads by biomarker type (21.1% share), while breast cancer testing dominates by indication (25.1% share). North America captures 52.1% of global market revenue.

07/22/2026, 4:49 AM • GlobeNewswire

PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight

A comprehensive analysis reveals over 180 companies developing 200+ PD-1 and PD-L1 inhibitor drugs across various clinical stages. The report highlights major pharmaceutical players advancing pipeline therapies for multiple cancer indications, with approximately 15+ drugs in late-stage development and 30+ in mid and early stages. Recent developments include FDA breakthrough designations and positive clinical trial results for combination therapies.

07/21/2026, 1:00 PM • GlobeNewswire

Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate

The global cancer biomarkers market is valued at USD 28.25 billion in 2026 and is projected to reach USD 54.48 billion by 2032, expanding at an 11.6% CAGR. Growth is driven by rising cancer incidence, technological advances, adoption of precision medicine, and liquid biopsy techniques. Omics technologies and breast cancer diagnostics lead segment growth, while Asia-Pacific emerges as the fastest-growing region. Key players include Roche, Thermo Fisher, Illumina, and Agilent Technologies.

07/17/2026, 6:44 AM • GlobeNewswire

Bioinformatics Collaboration and Licensing Deals 2019-2026 | Compare Upfronts, Milestones, and Royalties for 1,230+ Deals

ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions across the bioinformatics industry.

07/17/2026, 5:54 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

07/15/2026, 11:00 AM • GlobeNewswire

Global Biochemistry Analyzer Market to Reach $8.18 Billion by 2035 as Diagnostic Testing Demand Accelerates

The global biochemistry analyzer market is projected to reach $8.18 billion by 2035, driven by increasing diagnostic testing demand, adoption of fully automated systems, artificial intelligence integration, and rising preventive screening programs. The market encompasses various product types, modalities, and applications across hospitals, diagnostic centers, and research institutions globally.

07/15/2026, 5:24 AM • GlobeNewswire

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities include oral GLP-1 agonists, next-generation incretin drugs, and convenient non-injectable options for obesity management.

07/15/2026, 4:15 AM • GlobeNewswire

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy

The FDA has granted Priority Review to Roche's Gazyva/Gazyvaro (obinutuzumab) for treating primary membranous nephropathy (pMN), based on positive Phase III MAJESTY trial results showing 36.9% complete remission rate versus 5.7% with tacrolimus. If approved by November 2026, it would be the first FDA-approved therapy for pMN, a chronic autoimmune kidney disease affecting approximately 1.2 per 100,000 people annually in the US.

07/15/2026, 1:00 AM • GlobeNewswire

Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

The global blood glucose monitoring system market is valued at USD 16.8 billion in 2025 and is projected to reach USD 39.4 billion by 2035, growing at a CAGR of 8.9%. Growth is driven by AI-enabled monitoring systems, increasing diabetes prevalence, and rising adoption of home healthcare solutions. Key players include Medtronic, Abbott, Dexcom, and Roche, with recent partnerships like Abbott-Medtronic collaboration to integrate continuous glucose monitoring with automated insulin delivery systems.

07/14/2026, 12:30 AM • GlobeNewswire

What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It?

The Vanguard International Dividend Appreciation ETF (VIGI) offers exposure to 343 global stocks from developed markets with a low 0.07% expense ratio, but has delivered underwhelming returns and a modest 2.13% dividend yield. The fund is heavily concentrated in Japan (30.9%) and Canada (23%), and has been significantly outperformed by the S&P 500 over its track record. Analysts suggest more diversified alternatives like the Vanguard International High Dividend Yield ETF (VYMI) may be better for long-term investors.

07/09/2026, 11:05 AM • The Motley Fool

Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain

Despite expanding biologic adoption and evolving treatment strategies for systemic lupus erythematosus (SLE), research from Spherix Global Insights reveals substantial unmet need remains. While rheumatologists are advancing treatment strategies and increasing biologic utilization, nearly 80% of patients report moderate-to-severe disease with persistent symptoms and frequent flares. Approximately one-third of biologic-treated patients achieve only partial disease control. Recent approvals like Saphnelo® (anifrolumab) and anticipated approvals like Gazyva® (obinutuzumab) for non-renal SLE are expected to expand treatment options.

07/07/2026, 12:58 PM • GlobeNewswire

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Pharmaceutical Regulatory Affairs in Asia: Three-Day Online Course Opens Registration for October 20–22, 2026 Early-Bird Pricing Ends September 15

ResearchAndMarkets.com is launching a three-day online training course on pharmaceutical regulatory affairs in Asia (October 20-22, 2026) designed to help regulatory professionals navigate the region's complex and diverse compliance landscape. The course covers nine major Asian markets including China, India, Korea, and ASEAN countries, with instruction from experienced industry experts Alan Chalmers and Monica Dressler-Meyer. Early-bird pricing ends September 15, 2026.

07/06/2026, 10:55 AM • GlobeNewswire

Geopolitical Tensions Impacting AI in Pathology Market: Insights into US-Israel-Iran Conflicts on Market Dynamics

The global AI in Pathology market is valued at USD 28.75 Million in 2025 and expected to reach USD 68.81 Million by 2035 with a 9.12% CAGR. However, the US-Israel-Iran conflict is creating headwinds, causing IDC to revise US IT spending growth downward and disrupting cloud infrastructure and semiconductor supply chains. Despite challenges, AI infrastructure investment remains strong as enterprises seek automation solutions.

07/03/2026, 7:59 AM • GlobeNewswire